Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Background Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability to induce the production of inflam...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
BMJ Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/1543fccbb7ab42599845ba4d1df732b1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|